DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c0606e/product_profiles) has announced the addition of the "Product Profiles: Psoriasis - Novel therapies raise the bar for biologics" report to their offering.
The biologics market remains the most dynamic area within psoriasis treatment. Stelara (ustekinumab; Janssen Biotech) is displaying impressive uptake in the US and EU, to the detriment of established brands. With Abbott withdrawing regulatory filings of Ozespa (briakinumab), a key contender to Stelara in early 2011, this leaves Stelara to continue its ascendance across the seven major markets.
Features and benefits
- Gain insight into how new market entrants are positioned in the treatment algorithm versus established drugs, and how this may change in the future.
- Access Datamonitor's independent evaluation of prominent brands and pipeline agents for psoriasis, with physician perception of such therapies.
- Enhance understanding of market dynamics, using Datamonitor's assessment of clinical and commercial attributes of marketed and pipeline therapies.
- Review important clinical milestones of key late-stage pipeline candidates, with analysis of new clinical trial data.
The survey reveals that Stelara is gaining traction in moderate to severe patients at both first and second line and beyond, after 2 years in the US and EU markets. This is notable because typical first-line options Enbrel (etanercept) and Humira (adalimumab) have been available in these markets for 6 years and 4 years, respectively.
Interest in interleukin (IL) targets in the dermatology community continues to escalate. AIN457 leads the way in IL-17 targeting therapies and with strong efficacy data demonstrated in Phase II, it emerges as a notable pipeline candidate in the IL class to watch in the future.
Celgene's apremilast moved into Phase III in the US and EU during 2011. Still, late-stage data are needed, and it remains to be seen if it provides improved efficacy over established systemic drugs. This is vital because Pfizer's oral agent, tofacitinib, also in Phase III, has shown efficacy in line with leading brand Enbrel in Phase II trials.
Your key questions answered
- What impact could pipeline agents have on the future treatment of psoriasis, should they gain clinical and commercial success?
- What are the comparative strengths and weaknesses of the key psoriasis products and pipeline therapies?
- How do pipeline agents stack up against accepted gold-standard drugs in terms of their ability to meet clinical unmet needs in psoriasis treatment?
- To what extent could novel oral agents such as tofacitinib (CP-690,550; Pfizer) and apremilast (CC-10004; Celgene) challenge biologic brands?
- Will any products challenge Leo Pharma's dominance in the psoriasis topical market segment?
For more information visit http://www.researchandmarkets.com/research/c0606e/product_profiles